Wider Venture Funding Gap Raises Troubling Questions

a number of interesting jewels in these data:

• Software accounted for $4.5 billion (40 percent) of all the capital invested in the fourth quarter of 2015; healthcare was second, with $2.4 billion (21 percent).

• Overall, the average round size in software was $12.2 million, eclipsed by the $15.3 million for biotech. But both were greater than the $7.7 million for the media category—maybe a commentary on capital intensity?

• Bringing up the rear was telecom, which barely registered with only $67 million invested, or less than 1 percent of the amount in the fourth quarter.

• Cleantech saw $319 million invested in 144 companies (or $8.5 million per company).

• Nearly 19 percent of all capital invested in the fourth quarter was in “first-time” companies, although these round sizes were meaningfully smaller on average at $6.8 million—maybe suggesting a “newbie” discount?

• Silicon Valley companies captured $4.3 billion, while the New York metro area and New England saw $1.6 billion and $1.1 billion, respectively, invested. These three regions of the country accounted for 62 percent of all invested capital.

• Interestingly, the average round size for Silicon Valley companies was $16.1 million, as compared with the more frugal New England round sizes of $10.3 million.

• There were 370 venture deals in California (39 percent of the total), while only 97 (10 percent) and 94 (10 percent) in the New York metro area and New England, respectively.

• The top-10 investments were all over $100 million in size and accounted for $2.2 billion in aggregate, or 19 percent of the total amount invested in the fourth quarter.

So, less than 1 percent of all companies received 19 percent of all dollars invested in the fourth quarter. Not quite as bad as mankind writ large…but troublesome nonetheless.

[Editor’s note: This post first appeared on Greeley’s blog, “On the Flying Bridge.”]

Author: Michael A. Greeley

Michael is a General Partner at Flare Capital Partners. Prior to co-founding Flare Capital Partners, Michael was the founding General Partner of Flybridge Capital Partners where he led the firm’s healthcare investments. Current and prior board seats include BlueTarp Financial, Circulation, EndoGastric Solutions, Explorys, Functional Neuromodulation, HealthVerity, Iora Health, MicroCHIPS, Nuvesse, PolyRemedy, Predictive Biosciences, Predilytics, T2 Biosystems, TARIS Biomedical, VidSys and Welltok. Previously, Michael focused on emerging-growth company financings with Polaris Venture Partners, was a senior vice president and founding partner of GCC Investments, and held positions at Wasserstein Perella & Co., Morgan Stanley & Co. and Credit Suisse First Boston. Michael currently serves as chairman of the Entrepreneurship Committee of the Massachusetts Information Collaborative and on the Investment Committee for the Partners Innovation Fund and Massachusetts Eye & Ear Infirmary. Michael also serves on the Industry Advisory Board of the Cleveland Clinic and Boston Children’s Hospital, as well as serving on several other boards including the New England Investors’ Committee of Capital Innovation. He was the former chairman of the New England Venture Capital Association and on the Executive Committee of the board of the National Venture Capital Association. Named by the Boston Globe as the “Go-To” investor for life sciences, healthcare and medical devices and a Mass High Tech All-Star, Michael earned a B.A. with honors in chemistry from Williams College and an M.B.A. from Harvard Business School. Michael authors a blog focused on venture capital, innovation and healthcare at www.ontheflyingbridge.com.